Direct-to-consumer pharmaceutical advertising, prevalent in the US and New Zealand, has grown significantly since its legalization in 1997, with drug companies spending billions on ads annually. While the FDA has tried to regulate these ads to ensure accurate information is provided, enforcement has been challenging, with few violations reported. Consumer complaints and voluntary manufacturer submissions are the main mechanisms for monitoring noncompliance. The FDA has also launched programs to educate physicians and consumers on recognizing misleading ads. Critics suggest implementing warning labels for drugs, similar to those on cigarette packs, to increase transparency and protect public health.
Source link
With TV Drug Ads, What You See Is Not Necessarily What You Get
